Drug Profile
Research programme: macrocyclic peptide therapeutics - Mitsubishi Tanabe Pharma/PeptiDream
Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator PeptiGrowth
- Class Macrocyclic compounds; Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for research development in Unspecified in Japan
- 30 Mar 2020 PeptiDream and Mitsubishi Tana Pharma invented new joint venture company, PeptiGrowth to develop and commercialise peptide alternatives
- 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in Japan